Paul Walshaw, MD
Nephrology · Benson, AZNPI 1023014586
Payments from drug & device makers
Across 126 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$367
- Fresenius USA Marketing, Inc.$317
- AstraZeneca$311
- Otsuka America Pharmaceutical, Inc.$303
- GSK$197
- Bayer$187
- plus $820 from 18 others
What the payments were for
- Food & beverage$2,47999%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 18 | $367 |
| Fresenius USA Marketing, Inc. | 15 | $317 |
| AstraZeneca(2 entities) | 17 | $311 |
| Otsuka America Pharmaceutical, Inc. | 17 | $303 |
| GSK | 11 | $197 |
| Bayer | 12 | $187 |
| Vantive US Healthcare LLC | 1 | $149 |
| Mallinckrodt Hospital Products Inc. | 4 | $101 |
| Vifor Pharma, Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| Calliditas Therapeutics US Inc. | 3 | $61 |
| OPKO Pharmaceuticals, LLC | 3 | $47 |
| Ardelyx, Inc. | 2 | $45 |
| Akebia Therapeutics Inc | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Novo Nordisk | 1 | $28 |
| Lundbeck LLC | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 3 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| Nxstage Medical, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$149
How this compares
$2,501 in reported general payments places this provider in the 50th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcysbiCysteamine Bitartrate | 11 | $1,103,804 |
| JynarqueTolvaptan | 12 | $237,939 |
| FarxigaDapagliflozin Propanediol | 34 | $38,646 |
| NulojixBelatacept | 13 | $24,878 |
| ProcritEpoetin Alfa | 13 | $16,176 |
| JardianceEmpagliflozin | 11 | $15,921 |
| Calcitriol | 195 | $5,963 |
| Cinacalcet Hcl | 34 | $3,277 |
| Doxazosin Mesylate | 112 | $2,613 |
| Furosemide | 290 | $2,493 |
| Amlodipine Besylate | 341 | $2,219 |
| Losartan Potassium | 198 | $2,051 |
| Hydralazine Hcl | 101 | $1,984 |
| Fluconazole | 27 | $1,690 |
| Midodrine Hcl | 15 | $1,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProcysbi | $367 | $1,103,80411 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $303 | $237,93912 claims |
| AstraZenecaFarxiga | $311 | $38,64634 claims |
| Johnson & JohnsonProcrit | $13 | $16,17613 claims |
| Boehringer IngelheimJardiance | $18 | $15,92111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 259 nephrology providers in Arizona.
Other nephrology in Benson
- Peter SantosGlendale$3.6M
- Minesh RajpalPeoria$3.6M
- Leslie ThomasPhoenix$3.1M
- Kenneth BorenMesa$1.6M
- Hasan KhamashPhoenix$1.3M
- Roxana NeyraPhoenix$1M
- Mandeep SahaniMesa$945K
- Randy CooperPeoria$837K
- Amit FadiaTucson$396K
- Hassan HachemPhoenix$372K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.